https://scholars.lib.ntu.edu.tw/handle/123456789/195001
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor | 小兒科 | en |
dc.contributor.author | NI, YEN-HSUAN | en |
dc.contributor.author | HUANG, FU-CHEN | en |
dc.contributor.author | WU, TZEE-CHUNG | en |
dc.contributor.author | KONG, MAN-SHAN | en |
dc.contributor.author | JENG, YUNG-MING | en |
dc.contributor.author | CHEN, PEI-JER | en |
dc.contributor.author | TSUEI, DAW-JEN | en |
dc.contributor.author | CHEN, HUEY-LING | en |
dc.contributor.author | HSU, HONG-YUAN | en |
dc.contributor.author | CHANG, MEI-HWEI | en |
dc.creator | 倪衍玄;黃福辰;吳子聰;江文山;鄭永銘;陳培哲;崔道貞;陳慧玲;許宏遠;張美惠 | zh_TW |
dc.creator | NI, YEN-HSUAN;HUANG, FU-CHEN;WU, TZEE-CHUNG;KONG, MAN-SHAN;JENG, YUNG-MING;CHEN, PEI-JER;TSUEI, DAW-JEN;CHEN, HUEY-LING;HSU, HONG-YUAN;CHANG, MEI-HWEI | en |
dc.date | 2005 | en |
dc.date.accessioned | 2008-12-29T06:22:15Z | - |
dc.date.accessioned | 2018-07-11T17:55:38Z | - |
dc.date.available | 2008-12-29T06:22:15Z | - |
dc.date.available | 2018-07-11T17:55:38Z | - |
dc.date.issued | 2005 | - |
dc.identifier.uri | http://ntur.lib.ntu.edu.tw//handle/246246/94894 | - |
dc.description.abstract | Background: Lamivudine treatment in chronic carriers who acquired hepatitis B virus through maternal transmission were investigated. Methods : A total of 29 subjects (Male : Female, 24:5; mean age, 14.7 ± 5.6 years ) who were hepatitis B e antigen (HBeAg) seropositive for >6 months, alanine aminotransferase (ALT) was >1.3 times of upper limit of normal value, and receiving a 52 week-long treatment, received open-label lamivudine (3 mg/kg per day, maximum 100 mg/day). Another 29 subjects matched for gender, age, liver function, and HBeAg status followed up before the introduction of lamivudine served as the control group. The control group did not receive any treatment and were evaluated at week 52 after the onset of abnormal ALT. Mothers of all study subjects were hepatitis B surface antigen (HBsAg) carriers. A successful treatment response at week 52 was defined as: (i) undetectable hepatitis B virus DNA by real time polymerase chain reaction; (ii) normal ALT; and (iii) HBeAg/ anti-HBe seroconversion. Lamivudine- resistant YMDD mutants were checked at week 52. Results: The lamivudine group did not reach a better successful treatment response rate than the control group (17 vs 10%, P = 0.44), except in patients with a baseline ALT >5 times of the upper limit of normal value. YMDD mutants developed in 34% of patients in the lamivudine group. Conclusion: Lamivudine treatment is effective for maternally transmitted subjects with high ALT. | en |
dc.language | en-us | en |
dc.language.iso | en_US | - |
dc.relation | PEDIATRICS INTERNATIONAL v.47 n.4 pp.372-377 | en |
dc.relation.ispartof | PEDIATRICS INTERNATIONAL | - |
dc.subject | hepatitis | en |
dc.subject | B virus | en |
dc.subject | lamivudine | en |
dc.subject | maternal transmision | en |
dc.subject | real time polymerase chain reaction | en |
dc.subject | YMDD mutant | en |
dc.subject.classification | [SDGs]SDG3 | - |
dc.title | Lamivudine Treatment in Maternally Transmitted Chronic Hepatitis B Virus Infection Patients | en |
dc.type | journal article | en |
dc.relation.pages | 372-377 | - |
dc.relation.journalvolume | v.47 | - |
dc.relation.journalissue | n.4 | - |
item.fulltext | no fulltext | - |
item.openairetype | journal article | - |
item.languageiso639-1 | en_US | - |
item.openairecristype | http://purl.org/coar/resource_type/c_6501 | - |
item.grantfulltext | none | - |
item.cerifentitytype | Publications | - |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。